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OBJECTIVES This research was conducted to evaluate the role played by the humoral immune system in
cardiac dysfunction among dilated cardiomyopathy (DCM) patients, as enabled by immu-
noadsorption therapy (IA) that effectively removes functionally active cardiac autoantibodies
from plasma.
BACKGROUND Various circulating autoantibodies have been detected among patients suffering from DCM.
METHODS Before IA, antibodies were purified from plasma of 45 DCM patients (left ventricular ejection
fraction [LVEF] 30%). We analyzed the functional effects of antibodies (300 mg/l) on
calcium transients and on systolic cell shortening in adult rat cardiomyocytes. After this in
vitro analysis, IA was performed in four courses at one-month intervals until month 3.
RESULTS Antibodies from 29 patients induced a reduction (10%) in calcium transients (mean
reduction: 16.5  1.9%) and a simultaneous reduction (10%) of cell shortening (mean
reduction: 21.2  1.8%) on cardiomyocytes (p  0.001) (cardiodepressant group).
Antibodies from 16 patients did not significantly influence calcium transients and cell
shortening (10%) (non-cardiodepressant group). During the first IA course, the cardiode-
pressant group demonstrated an acute increase in cardiac index (CI) from 2.2 0.1 l/min/m2
to 2.9  0.1 l/min/m2 (p  0.001). In the non-cardiodepressant group, hemodynamics did
not significantly change throughout three months. After three months before the final IA
course (prolonged effects), the CI was 2.1  0.1 l/min/m2 in the non-cardiodepressant group
and 2.9  0.1 l/min/m2 in the cardiodepressant group (p  0.001). After three months
LVEF increased only in the cardiodepressant group: from 20.8  1% to 30.5  1% (p 
0.01).
CONCLUSIONS In the majority of DCM patients, disturbances of humoral immunity with production of
cardiodepressant antibodies may play a functional role in cardiac dysfunction. Evidence of
cardiodepressant antibodies predicts hemodynamic benefits during IA. (J Am Coll Cardiol
2004;44:829–36) © 2004 by the American College of Cardiology Foundationp
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filated cardiomyopathy (DCM) is a myocardial disease
haracterized by progressive depression of myocardial con-
ractile function and by ventricular dilatation (1). Distur-
ances of humoral immunity have been described in DCM
atients. A number of antibodies against various cardiac cell
roteins have been identified in DCM (e.g., antibodies
gainst mitochondrial proteins, contractile proteins, beta-1-
eceptors, and muscarinergic receptors) (2–6). Recent data
ndicate that cardiac antibodies play an active role in the
athogenesis of DCM and may contribute to cardiac dys-
unction in these patients (2,3). Removal of antibodies by
mmunoadsorption (IA) consequently improves cardiac
unction and alleviates myocardial inflammation in patients
ith heart failure (HF) due to DCM (7–11). Recent
vidence, furthermore, has enabled confirmation that IA
emoves functional active antibodies from the plasma of
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ald, Germany; †Medizinische Klinik I, Charité, Humboldt-Universität, Berlin,
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esearch and Technology) NBL3, and by the Deutsche Forschungsgemeinschaft
STA 628/2-1, 2-2).
Manuscript received July 30, 2003; revised manuscript received April 16, 2004,iccepted April 27, 2004.atients with DCM (10). These antibodies induce a nega-
ive inotropic effect in isolated rat cardiomyocytes through
epression of calcium transients. This cardiodepressant
ffect of the eliminated antibodies correlates with the acute
emodynamic improvement induced by IA (10). The pres-
nce of cardiodepressant antibodies in plasma of DCM
atients before IA may accordingly predict the potential
fficacy of this therapeutic approach.
The detection of cardiodepressant antibodies by means of
his bioassay system may be of essential therapeutic rele-
ance because the contribution of humoral activity with
roduction of cardiodepressant antibodies may differ among
CM patients. For treatment of patients with severe HF
ue to DCM, it is important to identify those patients who
ill receive hemodynamic benefit from IA. In addition, IA
epresents an invasive and expensive treatment. Hence,
redictors for hemodynamic improvement are necessary.
he present study accordingly investigated systematically
or the first time, and in a larger number of patients,
hether detection of cardiodepressant effects of antibodies
eceived from patients’ plasma before IA may be predictive
or short- and long-term hemodynamic improvement dur-
ng IA. Because, furthermore, IA effectively removes cardiac
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Humoral Immunity in Dilated Cardiomyopathy August 18, 2004:829–36utoantibodies from plasma, such a procedure enables eval-
ation of the role played by the humoral immune system in
ardiac dysfunction among DCM patients.
ETHODS
tudy protocol. A total of 45 DCM patients were admit-
ed to the study. Five patients had participated in earlier IA
tudies (12,13). All patients demonstrated left ventricular
LV) dysfunction (left ventricular ejection fraction [LVEF]
30%, as assessed by two-dimensional echocardiography),
s well as symptoms of severe chronic HF (New York Heart
ssociation [NYHA] functional class III to IV). We ex-
luded coronary heart disease by angiography, as well as
cute myocarditis among all patients by myocardial biopsy,
n accordance with Dallas criteria. An additional immuno-
istological analysis of CD3-positive lymphocytes, further-
ore, was performed in endomyocardial biopsies. Patients
ere excluded if they had suffered from active infectious
iseases, cancer, chronic alcoholism, or HF due to known
rigins (e.g., primary valvular disease). Patients with post-
artum cardiomyopathy were also excluded. All patients
ere treated with angiotensin-converting enzyme inhibi-
ors/angiotensin receptor antagonists, digitalis, and diuret-
cs. All patients had received stable oral medication for more
han three months before the study. Thirty-nine patients
ere treated with a beta-blocker. In these cases, doses of
eta-blockers had been stable for at least six months before
he present study. The hemodynamic inclusion criteria, as
stablished by a Swan-Ganz thermodilution catheter, were
ardiac index (CI) 2.5 l/min/m2 and/or pulmonary capil-
ary wedge pressure 16 mm Hg.
Written consent was obtained from each patient, and the
rotocol was approved by the Ethics Committees of the
niversity Hospital of Greifswald and of the Charité
niversity Hospital of Berlin, Germany.
reparation of plasma IgG. Before IA, antibodies were
solated from plasma by immunoaffinity purification using
nti-IgG-coupled sepharose (PlasmaSelect, Teterow, Ger-
any). Purification of antibodies was followed by dialyza-
ion (MWCO 100 KD, 1:100,000) against experimental
uffer (in mmol/l: 117 NaCl, 2.8 KCl, 0.6 MgCl2, 1.2
Abbreviations and Acronyms
CI  cardiac index
DCM  dilated cardiomyopathy
HF  heart failure
IA  immunoadsorption
Ig  immunoglobulin
LV  left ventricle/ventricular
LVEF  left ventricular ejection fraction
LVIDd  left ventricular internal diameter in diastole
NYHA  New York Heart Association
SVI  stroke volume index
SVR  systemic vascular resistanceH2PO4, 1.2 CaCl2, 20 glucose, and 10 HEPES; pH  i.3) for 30 h to remove molecules 100 KD. Antibodies
ere additionally heated (56°C, 30 min) for inactivation of
omplement (10). Aliquots of purified antibodies were
tored at 70°C before testing in isolated cardiomyocytes.
easurement of intracellular Ca2 transients and of
ystolic cell shortening. Ventricular cardiomyocytes from
dult Wistar rats (180 to 200 g) were isolated as described
lsewhere (10,14). The cardiomyocytes were suspended in
xperimental buffer and stained with the Ca2 fluorescent
robe Fura 2-AM (1 mol/l) for 10 min at 25°C. Single
ardiomyocytes were field-stimulated (1 Hz, 5 ms) and
uperfused continuously with experimental buffer (2 ml/
in) (10). Fluorescence measurements were recorded with a
ual-excitation, single-emission fluorescence photomulti-
lier system (IonOptix, Milton, Massachusetts). Changes in
ntracellular Ca2 transients were inferred from the ratio of
he fluorescence intensity at two wavelengths (15). A
ideo-imaging edge detector system (IonOptix) was used to
easure systolic cell shortening, as described (15). The
elative change of Ca2 transients and systolic cell shorten-
ng after superfusion of antibodies diluted with experimental
uffer (IgG 300 mg/l) were analyzed in isolated rat cardio-
yocytes as described recently (10,13).
Cardiodepressant effects were defined by a reduction of
he Ca2 transient (10%,  mean  2 SDs of controls)
nd simultaneous reduction of systolic cell shortening
10%,  mean  2 SDs of controls). Each purified
ntibody sample from one DCM patient was measured in
linded fashion, together with an age- and gender-matched
ontrol on the same cardiomyocyte preparation. The puri-
ed antibodies of controls and DCM patients were mea-
ured on at least six different cardiomyocytes of six different
ardiomyocyte preparations. The values given in the present
tudy express the mean obtained from these experiments.
ach cardiomyocyte was used for only a single investigation
f one sample. After this in vitro analysis (4 weeks before
A), IA was performed in all patients in four courses at
ne-month intervals until month 3.
mmunoadsorption. IgG extraction including all IgG sub-
lasses from the plasma took place with Ig-Therasorb
PlasmaSelect, Teterow, Germany), an anti-IgG immuno-
dsorber. Immunoadsorption was performed in four
ourses, at one-month intervals until month 3, as described
lsewhere (8). During the first course (course I), all patients
nderwent one IA session daily on three consecutive days.
fter the final IA session of each course, the patients
eceived for safety reasons 0.5 g/kg polyclonal IgG (Ven-
mmun N) to restore IgG plasma levels (8).
linical findings. Echocardiographic parameters were de-
ermined in all patients by two-dimensional echocardiogra-
hy, performed at baseline and after three months. The
esults were recorded, and a blinded reader performed
ff-line assessment of LVEF and left ventricular internal
iameter in diastole (LVIDd); LVEF was measured accord-
ng to the Simpson rule.
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August 18, 2004:829–36 Humoral Immunity in Dilated Cardiomyopathyemodynamics. We conducted right-heart catheteriza-
ion with a Swan-Ganz thermodilution catheter to evaluate
he hemodynamics of the patients. Measurements were
arried out four times per day. The interval between two
emodynamic measurements was at least three hours. He-
odynamic measurements were carried out four times a
ay, one day before and one day after the first IA course. In
ddition, before and after the fourth course (course IV),
emodynamic monitoring again took place four times a day.
tatistics. Results are expressed as mean SEM. Changes
n clinical outcomes were analyzed with respect to time by
pplying nonparametric multivariate analysis of variance for
epeated measurements, in a two-factorial design (group:
ardiodepressant vs. non-cardiodepressant and repetitions as
actors) (16). All four time points were accordingly com-
ared simultaneously on the corresponding response curves.
fter overall testing, post hoc analyses (Wilcoxon tests)
ere performed to detect specific differences between cer-
ain times of treatment as well as between treatment and
aseline. Differences were further analyzed between the two
roups with respect to certain time points by employing the
ann-Whitney U test. Adjustments were carried out for
ultiple comparisons (n  3) by conducting a sequentially
ejective test procedure according to Bonferroni-Holm (17).
isher exact test was performed to detect differences with
espect to gender between the subgroups. Changes were
nalyzed in NYHA classification before and after treatment
y means of singly ordered 2  3 (before) and 2  4 (after)
ontingency tables, with use of the exact Mantel-Haenszel
est of identically distributed rows (for treatments). Signif-
cance was assessed at the p  0.05 level. All numerical
alculations were performed using the packages SAS Ver-
ion 8.2 (SAS Institute Inc., Cary, North Carolina), SPSS
ersion 11 (SPSS Inc., Chicago, Illinois), and StatXact 5
CYTEL Software Corp., Cambridge, Massachusetts).
ESULTS
linical findings of all patients. A total of 45 DCM
atients was admitted to the study from 1998 to 2002. The
rst IA course induced hemodynamic improvement as
ollows: CI increased from 2.2  0.1 l/min/m2 to 2.7  0.1
/min/m2, and stroke volume index (SVI) increased from
9.6  1 ml/m2 to 36.0  1 ml/m2; (p  0.001 vs.
aseline). After three months, the hemodynamic improve-
ent persisted: before the last IA course, CI 2.6  0.1
/min/m2; SVI 35.0  1 ml/m2 (p  0.001 vs. baseline).
he last IA course induced moderate improvement in
emodynamic parameters: after the last IA course, CI 2.8
.1 l/min/m2; SVI 37.0  2 ml/m2 (p  0.001 vs. baseline;
 0.05 vs. before last IA course). After three months,
VEF increased from 21.4  1% to 28.1  1% (p  0.001
s. baseline). One female patient in the non-
ardiodepressant group died suddenly after the second IA
ourse. dn vitro findings. In contrast with antibodies obtained
rom age- and gender-matched healthy blood donors (con-
rols, n  45), antibodies from DCM patients induced a
eduction in Ca2 transients (DCM: 11.1  1.5%;
ontrols: 0.6  0.7%; p  0.001 vs. controls) and in cell
hortening (DCM: 14.7  1.7%; controls: 1.3  0.7%;
 0.001 vs. controls). However, the inotropic effects of
he antibodies on the isolated cardiomyocytes were not
niform among the patients. The antibodies obtained from
9 patients (cardiodepressant group) induced a significant
eduction (10%) in Ca2 transients (mean reduction:
16.5 1.9%) and cell shortening (mean reduction:21.2
1.8%) (p  0.001 vs. controls; p  0.001 vs. non-
ardiodepressant group) on cardiomyocytes (Fig. 1). In
ontrast, antibodies from 16 patients (non-cardiodepressant
roup) did not significantly influence calcium transients
mean reduction: 1.3  0.6%) or cell shortening (mean
eduction: 2.9  1.2%) (Fig. 1).
haracteristics of the subgroups at baseline. Table 1 lists
linical characteristics and echocardiographic parameters at
aseline. In the cardiodepressant group and in the non-
ardiodepressant group the following data were comparable:
ge, disease duration, NYHA functional classification, in-
ltration with lymphocytes in myocardial tissue, as well as
edical treatment (e.g., angiotensin-converting enzyme
nhibitors and beta-blockers). Left ventricular ejection frac-
ion and LVIDd were also similar in both groups. In four
atients of the cardiodepressant group (13.8%), and in three
atients of the non-cardiodepressant group (18.8%), an
ncreased number of lymphocytes ( 7 lymphocytes/mm2)
n endomyocardial biopsies were detectable. There were
ore female patients in the non-cardiodepressant group
han in the cardiodepressant group (p  0.05).
linical findings of the subgroups. During IA, total IgG
evels were effectively reduced in both groups by anti-IgG
A (IgG reduction in cardiodepressant group: 80.7  2%;
on-cardiodepressant group: 81.7  2%).
During the first IA course, hemodynamic parameters in
he non-cardiodepressant group did not alter significantly
Figs. 2, 3, and 4). No significant changes were determined
or the following parameters: CI, SVI, heart rate, and
ystemic vascular resistance (SVR).
In contrast, CI in the cardiodepressant group increased
rom 2.2  0.1 l/min/m2 to 2.9  0.1 l/min/m2 (p  0.001
s. baseline; p  0.001 vs. non-cardiodepressant group)
uring the first IA course (Fig. 2). Because heart rate
emained stable, SVI also significantly increased: from 30.8
1 ml/m2 to 38.3  2 ml/m2 (p  0.001 vs. baseline; p 
.001 vs. non-cardiodepressant group) (Fig. 3). Systemic
ascular resistance decreased from 1,343  45 dyne·s·cm5
o 1,010  39 dyne·s·cm5 (p  0.001 vs. baseline; p 
.001 vs. non-cardiodepressant group) (Fig. 4). Mean arte-
ial blood pressure, mean pulmonary arterial pressure, pul-
onary capillary wedge pressure, and right atrial pressureid not change significantly in either group.
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Humoral Immunity in Dilated Cardiomyopathy August 18, 2004:829–36The prolonged benefits of both groups were also different.
fter three months and before the last IA course in the
on-cardiodepressant group, none of the measured hemo-
ynamic parameters differed from those at baseline when
he study began (Figs. 2, 3, and 4). In contrast, hemody-
igure 1. Individual effects of purified antibodies (IgG 300 mg/l) on isol
ystolic cell shortening (B) during superfusion (% changes from baseline):
rom dilated cardiomyopathy (DCM) patients that induced cardiodepressan
id not influence Ca2 transients and systolic cell shortening (non-cardio
p  0.001 significantly different from non-cardiodepressant group.
Table 1. Characteristics of Patients at Baseline
All
Patien
(n  4
Age (yrs) 51.8 
Gender (male/female) 39/6
Disease duration (yrs) 4.7 
NYHA classification (n)
III/IV 33/12
Echocardiography
LVIDd (mm) 73.2 
LVEF (%) 21.4 
Hemodynamics
CI (l/min/m2) 2.2 
SVI (ml/m2) 29.6 
SVR (dyne·s·cm5) 1,379 
Medication
ACE inhibitor/AT-1 antagonist (n) 45
Beta-blocker (n) 39
Immunohistology
CD3 (cells/mm2) 3.9 
*p  0.05.
ACE angiotensin-converting enzyme; AT-1 angioten
ejection fraction; LVIDd  left ventricular internal diameter
volume index; SVR  systemic vascular resistance.amic improvement persisted in the cardiodepressant
roup: after three months, before the final IA course, CI
as 2.9  0.1 l/min/m2 in the cardiodepressant group (p 
.001 vs. baseline; p  0.001 vs. non-cardiodepressant
roup) (Fig. 2). Stroke volume index and SVR were,
eld-stimulated rat cardiomyocytes. Changes of Ca2 transients (A) and
dies from plasma of healthy blood donors (controls, n  45). Antibodies
cts (cardiodepressant group, n  29). Antibodies from DCM patients that
ssant group, n  16). ###p  0.001 significantly different from controls;
Cardiodepressant
Group
(n  29)
Non-Cardiodepressant
Group
(n  16)
50.3  1.8 54.5  2.0
28/1 11/5*
4.5  0.6 5.0  0.9
22/7 11/5
72.8  2 73.9  3
20.8  1 22.4  2
2.2  0.1 2.0  0.1
30.8  1 27.4  1
1,343  45 1,442  45
29 16
25 14
3.8  0.6 4.0  0.8
type 1 receptor; CI cardiac index; LVEF left ventricular
tole; NYHA  New York Heart Association; SVI  strokeated fi
antibo
t effe
deprets
5)
1.4
0.5
2
1
0.1
1
34
0.5
sin II
in dias
l
(
C
v
I
c
c
v
t
s
a
s
c
2
g
a
t
n
fi
g
g
n
i
c
t
D
A
p
d
p
p
p
i
a
o
i
a
p
m
a
F
p
(

I
F
i
c
d
F
b

s
s
F
(

s
s
833JACC Vol. 44, No. 4, 2004 Staudt et al.
August 18, 2004:829–36 Humoral Immunity in Dilated Cardiomyopathyikewise, significantly different compared with baseline
Figs. 3 and 4).
The final IA course induced moderate improvement of
I, SVI, and SVR in the cardiodepressant group (p  0.05
s. before last IA course) (Figs. 2, 3, and 4). After the final
A course, CI was 2.2  0.1 l/min/m2 in the non-
ardiodepressant group and 3.1  0.1 l/min/m2 in the
ardiodepressant group (p  0.001 vs. baseline; p  0.001
s. non-cardiodepressant group) (Fig. 2).
In addition, multivariate analyses regarding the entire
ime period from the first to the last course of IA revealed
ignificant differences between the two groups (p  0.001),
s well as significant changes in time for the cardiodepres-
ant group (p  0.001) with respect to CI, SVI, and SVR.
After three months, moreover, LVEF did not signifi-
antly increase in the non-cardiodepressant group: from
2.4  2% to 23.3  2% (p  NS). In the cardiodepressant
roup, improvement in hemodynamic parameters was par-
lleled by a comparable increase in LVEF: from 20.8  1%
o 30.5  1% (p  0.001 vs. baseline; p  0.01 vs.
on-cardiodepressant group) (Fig. 5).
After three months, examinations for NYHA HF classi-
cation revealed improvement in the cardiodepressant
roup (p  0.05 vs. baseline/vs. non-cardiodepressant
igure 2. Changes in cardiac index in the cardiodepressant group (solid
ars, n  29) and in the non-cardiodepressant group (open bars, n  16).
p  0.001 significantly different from baseline; p  0.001
ignificantly different from non-cardiodepressant group. IA  immunoad-
orption.
igure 3. Changes in stroke volume index in the cardiodepressant group
solid bars, n  29) and in the non-cardiodepressant group (open bars, n
16). p  0.001 significantly different from baseline; p  0.001
ignificantly different from non-cardiodepressant group. IA  immunoad-corption.roup). In contrast, non-cardiodepressant patients obtained
o relief from symptoms. The NYHA HF classification
mproved in the cardiodepressant group (p  0.001) in
omparison with the non-cardiodepressant patients after
reatment.
ISCUSSION
bnormalities of the humoral immune system are present in
atients with myocarditis and DCM. Several studies have
isclosed that IA, which removes autoantibodies from
lasma, may represent an additional therapeutic approach in
atients with HF due to DCM (7–11). The findings of the
resent study have revealed that abnormalities of humoral
mmunity with production of circulating cardiodepressant
ntibodies play a potential role in cardiac dysfunction in
nly a subgroup of DCM patients. The present study
nvestigated whether detection of cardiodepressant effects of
ntibodies received from patients’ plasma before IA may be
redictive for short- and long-term hemodynamic improve-
ent during IA. Identification of those patients with DCM
nd severe HF who will receive hemodynamic benefit from
igure 4. Changes in systemic vascular resistance (SVR) in the cardiode-
ressant group (solid bars, n  29) and in the non-cardiodepressant group
open bars, n  16). p  0.001 significantly different from baseline;
p  0.001 significantly different from non-cardiodepressant group.
A  immunoadsorption.
igure 5. Changes in LV ejection fraction as assessed by echocardiography
n the cardiodepressant group (solid bars, n  29) and in the non-
ardiodepressant group (open bars, n  16). p  0.001 significantly
ifferent from baseline; p  0.01 significantly different from non-
ardiodepressant group. IA  immunoadsorption.
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Humoral Immunity in Dilated Cardiomyopathy August 18, 2004:829–36A is important, because most of these patients are potential
andidates for heart transplantation. Furthermore, IA is an
xpensive and invasive therapeutic method.
linical findings and the detection of functionally active
ardiac antibodies. At baseline, no differences existed be-
ween the subgroups with regard to age, disease duration,
YHA class, LV function, infiltration by lymphocytes in
yocardial tissue, or hemodynamics. These findings indi-
ate that the detection of cardiodepressant antibodies was
ot associated with these clinical parameters. However, it is
mportant to point out that only patients with advanced HF
NYHA III/IV and ejection fraction 30%; CI 2.5
/min/m2 and/or pulmonary capillary wedge pressure 16
m Hg) were included in the present study. Owing to the
trict inclusion criteria of the present study, a relatively
omogenous patient group was admitted to the study. On
he other hand, these findings indicate that the prevalence
f cardiodepressant antibodies does not reflect severity of
yocardial damage in DCM but may rather imply revers-
ble impairment of cardiac function with the potential of
ecovery upon removal of these antibodies. Furthermore,
he comparable baseline findings indicate that other mech-
nisms are additionally involved in the pathogenesis of
CM. The potential of the different pathogenic factors
nvolved may differ among patients. The literature includes
ontradictory findings on associations between disturbances
f humoral immunity and clinical findings. A recent study
emonstrated that detection of the specific antibody against
he beta-1 receptor was more common among DCM
atients with poorer LV function (18). On the other hand,
aforio et al. (19) concluded that cardiac-specific autoanti-
odies in DCM become undetectable with disease progres-
ion. The proportion of female patients was higher in the
on-cardiodepressant group that did not receive hemody-
amic benefit during IA. However, a conclusion concerning
ender-based differences is limited by the small number of
emale patients included in the present study. On the other
and, clinical data on gender-based differences in the
athophysiology, treatment results, and outcomes of HF are
ell known (20).
A former study by Parrillo et al. (21) showed that
mmunomodulatory treatment using prednisone, which pri-
arily influences the cellular immune system, did not
nduce general improvement in LV function of DCM
atients. Only a subgroup of DCM patients with various
nflammatory markers in blood and in myocardial tissue
xperienced improvement in LVEF from prednisone (21).
n accordance with the findings of the present study,
ifferences concerning general clinical characteristics be-
ween the subgroups at baseline (e.g., age, NYHA func-
ional class, and disease duration) did not exist in the study
y Parrillo et al. (21).
athogenic importance of humoral immunity in DCM. A
ecent study has analyzed the pathogenic role of autoanti-
odies in the development of ventricular arrhythmias. In a
ubgroup of patients with DCM, antibodies against the carcolemmal Na-K-ATPase were detectable (22). Ventric-
lar tachycardias were more common in patients with
ntibodies against the Na-K-ATPase than in those without
uch antibodies. Autoantibodies could therefore be respon-
ible for the electrical instability in a subgroup of DCM
atients (22). A model of DCM was created by immunizing
abbits with peptides corresponding to the sequence of the
econd extracellular loop of either beta-1 adrenoceptors or
2-muscarinic receptors. High titers of anti-peptide anti-
odies were found in the sera. Both groups of immunized
abbits demonstrated morphologic heart alterations similar
o those found in human DCM (23). These findings also
ndicate that autoantibodies represent factors of clinical
mportance, and not an epiphenomenon.
The present study disclosed that, in the majority of
CM patients, humoral immunity may play an important
ole in cardiac dysfunction. In contrast with the non-
ardiodepressant group, hemodynamic improvement in the
ardiodepressant group was immediately detectable after the
rst IA course (after three consecutive days of IA). It is
nlikely that patients with a long history of HF and without
hange of medical treatment would experience such spon-
aneous hemodynamic improvement. In comparable control
atients who suffered from chronic HF caused by DCM,
nd who were included in former randomized studies, LV
unction remained stable for three months (8,11).
otential mechanisms of the cardiodepressant effects. Be-
ore testing of plasma on cardiomyocytes, antibodies were
urified by various methods. The antibodies were isolated
rom plasma by immunoaffinity purification by means of
nti-IgG-coupled sepharose. To remove smaller molecules,
urification of antibodies was followed by dialyzation
gainst experimental buffer. Antibodies were additionally
eated for inactivation of complement. In an earlier study,
arious cytokines were measured after such purification (10).
either TNF-alpha nor interleukin-1-beta, -6, -8, or -10
ere detectable. In a following study, the functional effects
f antibodies belonging to the IgG-3 subclass on cardiomy-
cytes were analyzed. Findings of this study disclosed that
he cardiodepressant effects on cardiomyocytes are mediated
y antibodies belonging to IgG-3 subclass (13). Therefore,
he removal of antibodies belonging to the IgG-3 subclass
ay represent one essential mechanism of IA. A previous
tudy analyzed the time course of cardiodepressant effects
nduced by the eliminated antibodies during IA (10).
ntibodies obtained during the first IA course on day 1
nduced a pronounced cardiodepressant effect on cardiomy-
cytes. Parallel to the reduction of total IgG during IA, the
egative inotropic effect of the eliminated antibodies col-
ected during days 2 and 3 was less pronounced (10).
A number of autoantibodies against cardiac cell proteins
ave been identified in DCM (2–6). However, the known
ardiac autoantibodies cannot explain the major in vitro
ndings of the present study (i.e., impairment of systolic cell
hortening by reduction of Ca2 transients without a
2hange in intracellular diastolic Ca level). Therefore,
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ens of the cardiac autoantibodies responsible for the
unctional effects.
emoval of beta-1-receptor autoantibodies and hemody-
amic improvement during IA. A recent study elucidated
he association between removal of beta-1-receptor autoan-
ibodies and the hemodynamic benefit during IA. Indepen-
ently of the analytical method, however, patients positive
nd negative for beta-1-receptor antibody received hemo-
ynamic benefits during IA (12). The beneficial hemody-
amic effects induced by IA are consequently not directly
ssociated with the removal of beta-1-receptor autoantibod-
es (12). Other cardiac antibodies may consequently be
ikewise involved in the hemodynamic effects of IA. We
ave recently shown that antibodies eliminated by IA
nduce a negative inotropic effect on cardiomyocytes. Fur-
hermore, immunoprecipitation has revealed that antibodies
liminated by IA are able to bind to different myocardial
roteins (10). These results, however, disclosed no differ-
nces between controls and DCM patients. The evident
bsence of a difference in myocardial protein patterns
etween patients and controls may arise from the fact that
he amount of cardiac antibodies is not great enough to
vidence a myocardial protein pattern for DCM patients. It
s further possible that IA removes functional active anti-
odies of low affinity (10). This hypothesis suggests that the
utative antibodies diffuse easily from their binding to the
ardiac antigens. The removal of antibodies by IA accord-
ngly induced immediate hemodynamic improvement. Fi-
ally, the functional activity of cardiac antibodies is not
aralleled by their binding properties. Jahns et al. (18)
howed that only a subgroup of antibodies that bind to the
eptide of beta-1-receptor can realize functional activity on
he native receptor. Further studies are therefore necessary
o elucidate the specific antigens of the cardiac autoantibod-
es that are responsible for the functional and clinical effects.
dditional mechanisms may likewise be involved in the
emodynamic effects of IA. Because direct influence of IA
n peripheral blood vessels cannot be excluded, the role of
he eliminated factors on SVR remains to be elucidated.
otential role of IgG substitution. After plasma IgG
epletion induced by IA, IgG was substituted for safety
easons (8). In addition to IA, IgG treatment additionally
nfluences the immune system through various mechanisms
24). Gullestad et al. (25) showed that IgG treatment may
nduce beneficial effects in patients with HF. The improve-
ent of LVEF has correlated with changes in inflammatory
nd anti-inflammatory mediators. In contrast, McNamara
t al. (26) showed that patients with acute cardiomyopathy
ho received IgG therapy (2 g/kg) obtained no further relief
rom symptoms than did placebo patients. In comparison
ith IgG treatment (2.0 g/kg), furthermore, substitution of
gG plasma level after IA was performed in our study with
low dosage of polyclonal IgG (0.5 g/kg). After substitu-
ion, the IgG level was comparable with the level before IA
data not shown). Hence, IgG substitution must be distin-uished from IgG treatment. Moreover, in a recent study
nvolving patients treated with protein-A IA and subse-
uent IgG substitution (0.5 g/kg), hemodynamic parame-
ers did not change significantly (13). These data indicate
hat IgG substitution with low dosage of IgG performed
fter IA does not influence the hemodynamic parameters
easured.
Our results indicate that the antibodies of DCM patients
re functionally active, by virtue of the evidence that they
nduce a decrease of cell contraction in isolated rat cardio-
yocytes by depression of calcium transients. These effects,
owever, are not detectable in all DCM patients. The short-
nd long-term hemodynamic benefit among DCM patients
uring IA was associated with the negative inotropic effects
f their antibodies received from patient plasma before IA.
he long-term effects of IA therapy on clinical outcome of
oth subgroups remain to be elucidated.
tudy limitations. In the present study, there was no
ignificant difference in CD3 lymphocytic infiltration
etween the cardiodepressant and the non-cardiodepressant
roup. An association, however, cannot be excluded be-
ween the detection of functional active antibodies and
dditional markers of inflammatory cardiomyopathy such as
urther phenotypes of immunocompetent infiltrates or en-
othelial expression of cell adhesion molecules in myocar-
ial tissue. Consequently, a higher prevalence of functional
ctive antibodies in patients with inflammatory cardiomy-
pathy cannot be definitely excluded.
onclusions. In the majority of DCM patients, function-
lly active autoantibodies are detectable that may play an
mportant role in cardiac dysfunction. Immunoadsorption
ccordingly induces beneficial effects only in this subgroup
f DCM patients. Evidence of cardiodepressant antibodies
redicts short- and long-term hemodynamic benefit during
A. Findings of the present study suggest that the humoral
mmune system, with production of circulating antibodies,
ay play an important role in cardiac dysfunction of a
ubgroup of DCM patients. On the other hand, the
umoral immune system may exert only a minor influence
n myocardial function among remaining DCM patients.
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